Year All20242023202220212020201920182017201620152014201320122011201020092008 Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 4, 2024 Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes September 3, 2024 Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results August 14, 2024 Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 August 7, 2024 Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout June 13, 2024 Protalix BioTherapeutics to Present at the 2024 BIO International Convention May 29, 2024 Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results May 10, 2024 Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 May 3, 2024 Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results March 14, 2024 Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 March 7, 2024
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 4, 2024
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes September 3, 2024
Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 August 7, 2024
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout June 13, 2024
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 May 3, 2024
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 March 7, 2024